Filofer30 mg

Filofer 30 mg is indicated for the treatment of iron-deficiency anemia (IDA) in adults and pediatric patients 10 years of age and older.

• Primary approved use: Treatment of iron-deficiency anemia, including in patients with underlying inflammatory bowel disease (IBD), where Filofer 30 mg has demonstrated favorable gastrointestinal tolerability compared with conventional ferrous iron salts.
• Niche/distinguishing use: Patients who have not responded adequately to, or who cannot tolerate, other oral iron products (e.g., ferrous sulfate, ferrous fumarate) due to gastrointestinal side effects.

Filofer 30 mg is not indicated for iron-deficiency states not related to true iron deficiency, nor for conditions where rapid iron repletion (e.g., severe symptomatic anemia requiring transfusion) is required.

Each capsule of Filofer 30 mg contains Filofer 30 mg equivalent to 30 mg of elemental iron. Ferric maltol is a stable, non-salt-based complex of ferric iron and maltol (a naturally occurring flavor compound), designed to deliver iron in a chemically distinct form from conventional ferrous iron salts.

Filofer 30 mg is an oral iron-replacement therapy developed as a novel, non-ionic ferric iron complex. Unlike traditional ferrous salts, Filofer 30 mg releases iron gradually across the intestinal mucosa, which is thought to reduce the amount of unabsorbed free iron reaching the lower gastrointestinal tract - a key mechanism behind its improved tolerability profile, particularly in patients with inflammatory bowel disease.

Filofer 30 mg is supplied as an oral capsule and is taken on an empty stomach, separate from food and other medications that can interfere with iron absorption.

Filofer 30 mg belongs to the class of oral iron replacement therapies (hematinics), specifically classified as a non-salt ferric iron complex, distinct from conventional ferrous salt preparations (e.g., ferrous sulfate, ferrous fumarate, ferrous gluconate).

Mechanism of Action

Filofer 30 mg is a stable complex of ferric iron (Fe3+) and maltol in a 1:3 ratio. It is designed to transport iron across the intestinal brush border membrane as an intact complex, where the iron is released intracellularly and then transferred to the systemic circulation, primarily bound to transferrin, for utilization in erythropoiesis and replenishment of iron stores.

Pharmacokinetics

Iron from Filofer 30 mg is absorbed predominantly in the duodenum and proximal jejunum. Because the complex minimizes the pool of free, unbound ionic iron in the gut lumen, gastrointestinal exposure to reactive iron species is reduced, which correlates with the improved tolerability seen in clinical studies compared with ferrous salts.

Take Filofer 30 mg capsules whole with water, on an empty stomach, approximately 1 hour before or 2 hours after a meal. Do not crush, chew, or open the capsule contents unless directed by a physician or pharmacist. Avoid taking within 4 hours of antacids, other oral iron products, or medicines known to interact with iron absorption (see Interactions).

Because Filofer 30 mg can bind with other substances in the gastrointestinal tract, several clinically significant interactions require dose separation of at least 4 hours between administration of Filofer 30 mg and the interacting drug:

• Tetracyclines and fluoroquinolone antibiotics (e.g., doxycycline, ciprofloxacin): Iron reduces absorption and efficacy of these antibiotics, and their concurrent use may also reduce iron absorption from Filofer 30 mg. Separate dosing by at least 2-4 hours.
• Levothyroxine: Iron may reduce absorption of levothyroxine, potentially reducing its effectiveness; separate administration.
• Bisphosphonates and penicillamine: Reduced absorption of these agents with concurrent iron; separate dosing.
• Antacids and proton pump inhibitors (PPIs): May reduce absorption and efficacy of Filofer 30 mg by altering gastric pH; avoid co-administration where possible.
• Other oral iron products or dimercaprol: Avoid concurrent use due to increased risk of toxicity/reduced efficacy.

Food, particularly dairy products, tea, and coffee, may also reduce iron absorption from Filofer 30 mg - hence the recommendation to take it on an empty stomach.

A key advantage of Filofer 30 mg is generally better gastrointestinal tolerability compared with conventional ferrous iron salts; nonetheless, adverse effects can still occur, most commonly gastrointestinal in nature.

Common

• Flatulence
• Abdominal pain/discomfort
• Diarrhea
• Constipation
• Discoloration of stool (dark/black stools - an expected, harmless effect of oral iron)
• Nausea, vomiting, bloating

Less Common/Serious

• Flare of underlying inflammatory bowel disease (in patients with IBD)
• Signs of iron overload with prolonged inappropriate use (see Overdose)

In clinical trials, fewer than 5% of patients discontinued Filofer 30 mg due to side effects, reflecting its favorable tolerability profile relative to ferrous salts.

Pregnancy

Filofer 30 mg should be used during pregnancy only if clearly needed and if the potential benefit justifies the potential risk to the fetus; consult a physician before use. Available data suggest the intact Filofer 30 mg complex is not expected to result in significant fetal exposure, but clinical experience with this specific formulation in pregnancy remains limited. Iron supplementation in general is standard of care in pregnancy when iron-deficiency anemia is clinically confirmed, under physician guidance.

Lactation

Filofer 30 mg is not expected to be systemically absorbed to a significant degree, and clinically meaningful exposure of a breastfed infant is not anticipated; however, data specific to breastfeeding are limited. Use only under medical supervision while breastfeeding.

Use Filofer 30 mg with caution in the following situations:

• Inflammatory bowel disease (IBD): Monitor for signs of disease flare, as gastrointestinal symptoms of IBD may overlap with or be aggravated by iron therapy.
• Risk of iron overload: Periodic monitoring of iron parameters (ferritin, transferrin saturation) is recommended, especially with prolonged use, to avoid accumulation to toxic levels; see Contraindications for absolute iron-overload conditions.
• Accidental pediatric ingestion: Iron-containing products are a leading cause of fatal poisoning in children under 6 years when ingested accidentally; keep out of reach of children (see Overdose).
• Diagnostic interference: Iron therapy can interfere with the diagnosis of occult gastrointestinal bleeding (e.g., stool occult blood tests) due to stool discoloration.
• Concomitant medications: See Interactions for required dose separation with several drug classes.

Acute overdose of Filofer 30 mg is a potential concern, although this formulation is generally associated with a lower acute toxicity risk than conventional ferrous iron salts due to its controlled-release mechanism. Nonetheless, iron ingestion in excess of recommended doses - particularly accidental ingestion by children - can be serious or fatal.

Early symptoms of iron overdose may include nausea, vomiting, abdominal pain, and diarrhea, which can progress to more severe systemic toxicity if untreated. In case of suspected overdose, seek immediate medical attention or contact a poison control center/emergency services without delay. Do not attempt specific home treatment. Management in a medical facility may include supportive care and, where indicated, chelation therapy under specialist supervision.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Renal Impairment

No well-established dose adjustment is defined for patients with renal impairment; use with caution and physician oversight.

Hepatic Impairment

No well-established dose adjustment is defined for patients with hepatic impairment; use with caution and physician oversight.

Elderly

No specific dose adjustment is required based on age alone; use with routine clinical monitoring as in other adult patients.

Inflammatory Bowel Disease

Filofer 30 mg is commonly used in this population due to favorable GI tolerability; monitor for disease activity as noted in Precautions.

Treatment with Filofer 30 mg is typically continued for a minimum of 12 weeks, with duration extended as needed based on normalization of hemoglobin and iron stores (ferritin), under physician guidance and periodic laboratory monitoring.

Oral iron replacement therapy; non-salt ferric iron complex (hematinic agent).

Filofer 30 mg delivers iron as a stable, non-ionic ferric-maltol complex that is absorbed intact across the intestinal mucosa, then dissociated intracellularly to release iron for transport via transferrin to sites of erythropoiesis and iron storage, while limiting the pool of free reactive iron within the gut lumen.

Filofer 30 mg is approved for use in pediatric patients 10 years of age and older for the treatment of iron-deficiency anemia, using the same dosing regimen as adults (one capsule twice daily). Safety and effectiveness in children younger than 10 years of age have not been established. Caregivers should be counseled on safe storage, as accidental ingestion of iron products is a leading cause of fatal poisoning in young children.